Officials at Asia's largest drugmaker are proposing to settle more than 8,000 lawsuits in federal and state courts across the United States. Such an agreement would constitute a payment of approximately $275,000 for each individual case.
…
Former Actos users have argued that Takeda executives ignored or downplayed concerns about the drug's carcinogenic potential before it went on sale in the United States in 1999 and misled US regulators about the drug's risks.
[… continues]Jeff Feeley April 1, 2015 – Bloomberg Business
FDA. Actos (pioglitazone): Ongoing Safety Review – Potential Increased Risk of Bladder Cancer
Editor's note: We report the above for the sake of the record, without thereby expressing judgments or evaluations that are not our responsibility
Takeda Pharma sinks in Tokyo (-6%) on US sanctions for 2.4 billion $
FTA Online News
Takeda Pharmaceutical opened the session on the Nikkei (after the Tokyo Stock Exchange had been closed on Wednesday for holidays) nearly losing 6% following the communication of the settlement of the US lawsuits relating to the concealment of the risk of developing cancer linked to the use of the antidiabetic Actos. The largest Japanese pharmaceutical group will pay penalties for a total of 2.4 billion dollars, a figure that will probably result in Takeda's first operating loss since 1949 (the year of its listing). The stock's decline in Tokyo narrowed to around 2% during the session.
(RR) 04/30/2015 08.20 International stock exchanges – ECONOMY – THE PRESS
